Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT05231122

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re…

This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ova…

United States80 participantsStarted 2024-03-12

Treatment: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab

All recent trials (10 shown)

Active — Not RecruitingPhase 3

NCT02446600

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usu…

This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating…

United States579 participantsStarted 2016-03-28

Treatment: Biospecimen Collection, Carboplatin

Active — Not RecruitingPhase 1

NCT04092270

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansi…

This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patie…

United States54 participantsStarted 2020-05-07

Treatment: Biospecimen Collection, Computed Tomography

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re…

All recent trials (10 shown)

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usu…

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansi…

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re…

All recent trials (10 shown)

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usu…

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansi…

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovaria…

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Prim…

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and…

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients Wit…

A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurre…

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients Wit…